Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Allergan buys Aczone Gel 5 percent from QLT USA
Irvine, Calif. - Allergan has announced it has entered an agreement with QLT USA to purchase Aczone (dapsone) Gel 5 percent, according to socalTech.com.
Irvine, Calif.
- Allergan has announced it has entered an agreement with QLT USA to purchase Aczone (dapsone) Gel 5 percent, according to socalTech.com.
Allergan will pay about $150 million for all assets related to Aczone, a topical treatment for acne vulgaris, which could reach revenues in excess of $75 million per year.
Related Videos
Related Content
